Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Relief therapeutics  /  Relief therapeutics Holding

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 1,255 13 mei 2024 17:12
  • +0,005 (+0,40%) Dagrange 1,250 - 1,300
  • 10.362 Gem. (3M) 17,1K

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 101 102 103 104 105 ... 456 »» | Laatste | Omlaag ↓
  8. TraceyH 26 augustus 2020 12:24
    Nou die DZR..heeft er werkelijk op elk forum een handje ban om te ' terroren'..heeft waarschijnlijk zelf geen leven.
    Ik heb hem zien tekeergaan bij Novacyt en Pharming....altijd uiteindelijk zonder goed onderbouwde argumenten.
    Novacyt was ook niets...wel gekocht voor 0.45 c en verkocht op 5.45....maar hij wist t allemaal beter...ze staan nu nog op ruim 3 euro...dussss
  9. [verwijderd] 26 augustus 2020 12:29
    quote:

    TraceyH schreef op 26 augustus 2020 12:24:

    Nou die DZR..heeft er werkelijk op elk forum een handje ban om te ' terroren'..heeft waarschijnlijk zelf geen leven.
    Ik heb hem zien tekeergaan bij Novacyt en Pharming....altijd uiteindelijk zonder goed onderbouwde argumenten.
    Novacyt was ook niets...wel gekocht voor 0.45 c en verkocht op 5.45....maar hij wist t allemaal beter...ze staan nu nog op ruim 3 euro...dussss
    Lekker je eigen plan trekken inderdaad!

    DL 0,338
    DH 0,478
    RT 0,46

    Welke kant gaan we op?
  12. [verwijderd] 26 augustus 2020 12:54
    quote:

    TraceyH schreef op 26 augustus 2020 12:29:

    En DZR ook relief aangekocht voor 0.16 c?
    Nee natuurlijk niet, anders geven we niet zoveel af.
    Dit aandeel kan, net als Novacyt destijds, opeens hard gaan.
    Ik zie er echt potentie in....geduld...geduld
    Trollen worden gevoed door dit soort posts.
  13. forum rang 5 MisterBlues 26 augustus 2020 13:02
    Uitstekende samenvatting van alles dat speelt van investorshangout. Opvallend is ook toezegging dat geen nieuwe aandelenuitgifte nodig is voor inhaler-onderzoek volgens CEO door voorfinanciering GEM.

    For potential new investors, or for longs who who need reassurance, the insiderfinancial article is a good summary. For an even better bullet point summary, this is a repost from investorshangout (https://investorshangout.com/post/view?id=5870444):

    Summary of known facts about RLFTF: Aviptadil RLF-100 VIP

    • Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.

    • Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.

    • An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.

    • Aviptadil is inexpensive and easy to manufacture.

    • Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.

    Stock/Company

    • Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC). Dit klopt niet meer: het OTC QB, er is een uplisting geweest.

    • NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.

    • Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.

    • Unconfirmed: Most of the outstanding shares are owned by insiders.

    • Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.

    • Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.

    Manufacturing and Distribution

    • Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.

    • Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.

    • 2 Partnership arrangements are expected to be announced soon.

    • “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt

    • “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt

    • “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt

    Clinical Trials

    • Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.

    • Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.

    • Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.

    • Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
  16. forum rang 5 MisterBlues 26 augustus 2020 13:14
    Uitstekende samenvatting van alles dat speelt van investorshangout. Opvallend is ook toezegging dat geen nieuwe aandelenuitgifte nodig is voor inhaler-onderzoek volgens CEO door voorfinanciering GEM.

    For potential new investors, or for longs who who need reassurance, the insiderfinancial article is a good summary. For an even better bullet point summary, this is a repost from investorshangout (https://investorshangout.com/post/view?id=5870444):

    Summary of known facts about RLFTF: Aviptadil RLF-100 VIP

    • Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.

    • Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.

    • An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.

    • Aviptadil is inexpensive and easy to manufacture.

    • Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.

    Stock/Company

    • Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC). Dit klopt niet meer: het OTC QB, er is een uplisting geweest.

    • NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.

    • Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.

    • Unconfirmed: Most of the outstanding shares are owned by insiders.

    • Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.

    • Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.

    Manufacturing and Distribution

    • Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.

    • Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.

    • 2 Partnership arrangements are expected to be announced soon.

    • “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt

    • “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt

    • “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt

    Clinical Trials

    • Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.

    • Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.

    • Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.

    • Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
  20. forum rang 5 MisterBlues 26 augustus 2020 13:47
    Uitstekend gedaan, TraceyH, het artikel brengt niets nieuws maar wel overzicht. We kunnen allemaal het compliment van DZR in ons zak steken dat de schrijver zich gebaseerd moet hebben op dit draadje. :)

    Tot vanavond. Ik moet aan het werk. Relief is top entertainment en meer...
9.103 Posts
Pagina: «« 1 ... 101 102 103 104 105 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!